ePrints

Hodgkin lymphoma in the elderly: A clinical review of treatment and outcome, past, present and future

Lookup NU author(s): Professor Stephen Proctor, Dr Jennifer Wilkinson, Dr Michal Sieniawski

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Hodgkin lymphoma (HL) is a curable cancer in the vast majority of patients under the age of 60 years. Because of the rarity of the disease in older people, and age related factors such as co-morbidity, inability to tolerate aggressive chemotherapy, poor ECOG status at presentation and issues relating to frailty, the literature is sparse and no prospective randomised studies exist. The incidence of HL in the over 60s range between 10% and 20% of the disease overall and, as a potentially curable cancer, new specific treatment approaches designed for the elderly are necessary. This review discusses the available data in relation to treatments and outcome to date, and proposes how future studies and evaluations might be constructed for this disease. The SHIELD study (Study of Hodgkin lymphoma in the Elderly/Lymphoma Database) is a current example of an approach aimed at objectively defining some of the difficulties of this patient population. (c) 2008 Elsevier Ireland Ltd. All rights reserved.

Publication metadata

Author(s): Proctor SJ, Wilkinson J, Sieniawski MK

Publication type: Article

Publication status: Published

Journal: Critical Reviews in Oncology / Hematology

Year: 2009

Volume: 71

Issue: 3

Pages: 222-232

ISSN (print): 1040-8428

ISSN (electronic): 1879-0461

Publisher: Elsevier Ireland Ltd

URL: http://dx.doi.org/10.1016/j.critrevonc.2008.12.007

DOI: 10.1016/j.critrevonc.2008.12.007

Altmetrics

Share